Inflammation is involved in cardiovascular diseases. Some studies have found that the Mediterranean diet (MD) can reduce serum concentrations of inflammation markers. However, none of these studies have analyzed the influence of genetic variability in such a response. Our objective was to study the effect of the -765G.C polymorphism in the cyclooxygenase-2 (COX-2) gene and the -174G.C polymorphism in the interleukin-6 (IL-6) gene on serum concentrations of IL-6, C-reactive protein, intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule-1 as well as their influence on the response to a nutritional intervention with MD. An intervention study in a high cardiovascular risk Mediterranean population (314 men and 407 women) was undertaken. Participants were randomly assigned to consume a low-fat control diet or a MD supplemented with virgin olive oil or nuts. Measures were obtained at baseline and after a 3-mo intervention period. At baseline, the COX-2 -765G.C polymorphism was associated with lower serum IL-6 (5.85 6 4.82 in GG vs. 4.74 6 4.14 ng/L in C-allele carriers; P ¼ 0.002) and ICAM-1 (265.8 6 114.8 in GG vs. 243.0 6 107.1 mg/L in C-carriers; P ¼ 0.018) concentrations. These differences remained significant after multivariate adjustment. The IL-6 -174G.C polymorphism was associated with higher (CC vs. G-carriers) serum ICAM-1 concentrations in both men and women and with higher serum IL-6 concentrations in men.
Introduction
High serum concentrations of inflammation and endothelial dysfunction markers, such as interleukin-6 (IL-6), 21 C-reactive protein (CRP), soluble intercellular adhesion molecule 1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) are associated with higher cardiovascular risk (1, 2) . These markers can be modulated by dietary intake (3) . Moreover, the Mediterranean diet (MD) as a whole or a high consumption of typical foods from this diet, has been proposed as a good reducer of their serum concentrations in several studies (4) (5) (6) (7) (8) . However, none of these studies have analyzed the influence of genetic variability in the modulation of the effects. In the era of nutrigenomics, it is necessary to provide information on this issue to gain more specific knowledge on individualization of diet and to more accurately interpret epidemiological findings (9) . The discovery of cyclooxygenase-2 (COX-2)-inhibitory activity in a component of olive oil (oleocanthal) offers a possible mechanistic explanation for the link between the MD, rich in olive oil, and its cardiovascular benefits (10) and stresses the importance of COX-2 in the inflammatory process linked to a MD. COX-2 is a key regulatory enzyme in eicosanoid metabolism, converting free arachidonic acid to prostaglandin. The -765G.C polymorphism (rs20417) in the COX-2 gene locates within a putative binding site for the stimulatory protein-1 and has significantly lower (230%) promoter activity than the -765G allele (11) . It has been associated with lower concentrations of CRP, IL-6, other inflammation markers, and cardiovascular risk (11) (12) (13) (14) (15) . Induction of COX-2 precedes IL-6 gene expression (16) . IL-6 gene variation also may contribute to serum differences in inflammation markers. Most studies focused on the -174G.C polymorphism (rs1800795), which has been associated with increased IL-6 and CRP concentrations, increased insulin resistance, and higher cardiovascular disease risk in C allele carriers in several studies (17) (18) (19) (20) . However, the reported associations are very controversial, suggesting potential dietary interactions (21, 22) . Therefore, our objective was to study the effect of the -765G.C COX-2 and the -174G.C IL-6 polymorphisms on concentrations of serum inflammation markers in a high cardiovascular risk Mediterranean population as well as their influence on the response to a 3-mo intervention with MD.
Materials and Methods
Study design and participants. The Prevenció n con Dieta Mediterrá -nea study is a parallel-group, multicenter, controlled, randomized clinical trial (ISRCTN35739639) aimed at assessing the effects of the MD on the primary prevention of cardiovascular disease (main outcome). It is currently taking place (anticipated completion date, December 2010). Here, we included data from the first evaluation study designed to assess the 3-mo effects of the dietary interventions (3 groups) on inflammation markers and other intermediate phenotypes (6) . Briefly, from October 2003 to March 2004, potential high cardiovascular risk participants (n ¼ 930) were selected by physicians in Primary Care Centers in Spain. Eligible participants were community-dwelling people (55-80 y of age for men; 60-80 y of age for women) who fulfilled at least 1 of 2 criteria: type 2 diabetes; $3 cardiovascular risk factors (current smoking, hypertension, hypercholesterolemia, BMI $25 kg/m 2 , or a family history of premature cardiovascular disease). Exclusion criteria were cardiovascular disease, any severe chronic illness, drug or alcohol addiction, history of allergy, or intolerance to olive oil or nuts. We excluded 158 participants before randomization. Of the 772 participants who entered the study, we analyzed 721 Caucasian participants (314 men and 407 women) who completed the 3-mo intervention trial and had both the COX-2 -765G.C and the IL-6 -174G.C polymorphisms determined. All participants provided written informed consent to participate in the study. The Institutional Review Board of each participating center approved the study protocol.
Dietary intervention. After the screening visit, each center randomly assigned the high cardiovascular risk participants to 1 of 3 diet groups using a computer-generated, random number sequence. The groups were: 1) MD supplemented with extra virgin olive oil (MD1VOO); 2) MD supplemented with 30 g/d of mixed nuts (MD1NUTS); and 3) a control group (intervention with a low-fat diet) (CTRL). A registered dietitian gave personalized dietary advice to each participant, with recommendations on the desired frequency of specific food intake. Informative group talks and provision of written material with descriptions of the MD and typical foods were conducted [Supplemental document 1 (in English) and 2 (in Spanish)]. The general guidelines to the 2 MD groups were for abundant use of virgin olive oil for cooking and dressing of dishes; consumption of $2 servings/d of vegetables (at least 1 of them as salad); $3 servings/d of fresh fruits (including natural juices); $3 servings/wk of legumes; $3 servings/wk of fish or seafood (at least 1 of fatty fish); $3 servings/wk of nuts or seeds; selected white meats (i.e. poultry without skin or rabbit) instead of red meats or processed meats (i.e. burgers and sausages); and regularly cooking with salsa made with minced tomato, garlic, and onion simmered in olive oil, adding other aromatic herbs or not, for dressing different dishes. Negative recommendations were also given to eliminate or limit the consumption of cream, butter, margarine, sweetened drinks, confectionery, industrial bakery products, chips or similar products, and precooked dishes or foods. No energy restrictions were suggested. In addition, depending on group assignment, participants were given either free virgin olive oil (1 L/wk) for cooking and dressing or free sachets of nuts (raw and unsalted) for daily consumption [walnuts (15 g/d), hazelnuts (7.5 g/d), and almonds (7.5 g/d)] for 3 mo. Participants in the CTRL group were advised by the dietitian to reduce intake of all types of fat and were given a leaflet with written recommendations following the AHA guidelines (23) .
Dietary measures. Food consumption at baseline and after the 3-mo intervention period was determined by a previously validated FFQ (24, as well as by a simplified 14-item questionnaire indicating a score of higher adherence to the traditional MD. Values of 0 or 1 were assigned to each of 14 dietary components (6) .
Biochemical analyses. Before and after 3 mo of intervention, blood and urine (first morning void) samples were obtained after an overnight fast. They were shipped to central laboratories and frozen at 280°C. Determinations at baseline and after 3 mo for an individual were conducted in the same batch and in duplicate. Serum glucose, cholesterol, triglycerides, HDL cholesterol (HDL-C) and LDL cholesterol (LDL-C) were determined as previously reported (6) . Serum concentrations of high-sensitivity CRP were measured by particle enhanced immunonephelometry in a Synchron LXi 725-Synchron Access Clinical system (Beckman Coulter). The lower limit of detection for this assay was 0.1 mg/L. Inter-and intra-assay CV were 1.8 and 0.9%, respectively. We measured serum soluble ICAM-1 and VCAM-1 (R&D Systems) and IL-6 (Biosource International) using standard ELISA assays. Intraand interassay CV for ICAM-1, VCAM-1, and IL-6 ranged between 1.8 and 5.4% and between 0.9 and 9.9%, respectively. In addition, biological assessment of the intervention compliance was performed on a subsample (n ¼ 273) of participants selected at random from the 3 groups. Tyrosol and hydroxytyrosol, the major phenolic compounds in olive oil, were measured in urine by GC-MS on a Hewlett-Packard gas chromatograph (HP5980) coupled to a mass spectrometer detector system (HP5973) as biomarkers of compliance of the MD1VOO group (6). The plasma a-linolenic, measured by GC on a Shimadzu GC-2010 gas chromatograph (Shimadzu), was used as biomarker of compliance of the MD1NUTS group (6).
DNA extraction and genotyping. Genomic DNA was extracted from buffy-coat with the MagNaPure LC DNA Isolation kit (ROCHE Diagnostics). The COX-2 -765G.C polymorphism was determined as previously described (11) . The IL-6 -174G.C was genotyped on a 7900HT Sequence Detection system (Applied Biosystems) using a fluorescent allelic discrimination TaqMan assay.
Statistical analysis. Triglyceride, CRP, VCAM-1, ICAM-1, and IL-6 concentrations were log-transformed for the statistical analyses. Pearson x 2 and Fisher tests were used to test differences in percentages. T and ANOVA tests were applied to compare crude means of inflammation markers. Values in tables are means 6 SD or means (95% CI). We carried out multivariate adjustments of the association by ANCOVA with post hoc comparisons (Tukey's honestly significant difference). We adjusted models for the potential confounders: age, gender, BMI, diabetes, dyslipemia, hypertension, tobacco smoking, adherence to MD score (at baseline), and medication use (antihypertensive drugs, statins, antidiabetic drugs, nonsteroidal antiinflammatory agents, and aspirin). The statistical homogeneity of the effects by gender was tested using interaction terms. We examined 3-mo changes in dietary and inflammation markers with ANCOVA for repeated measures, including control for potential confounders. We also performed ANCOVA for repeated measures to test gene 3 diet interactions. In these analyses, we studied the statistical effects of the genotype alone, the effect of the diet (change in the corresponding inflammation marker over the intervention period), and the effect of the interaction of both factors (genotype and diet), which is indicative of the different response to diet depending on the polymorphism analyzed. Statistical analyses were performed with the SPSS package, version 15.0. Our study, including 721 participants equally distributed into 3 intervention groups, was adequately powered to detect significant gene 3 diet interaction terms considering a mean dietary effect of 15%, a frequency of 35% for the carriers of the minor allele and a mean difference of 10% between genotype groups, an a of 5% and a standard b of 20% in a repeated-measures model. The greater the difference between groups for a specific parameter, the higher was the corresponding statistical power in the specific analysis.
Results
Men and women who completed the study ( Table 1 ) did not differ in genotype distribution for either the COX-2 -765G.C or for the IL-6 -174G.C variants. Frequencies of these polymorphisms did not differ according to the participant recruitment center (P ¼ 0.135 for the COX-2 distribution by centers and P ¼ 0.804 for the IL-6 polymorphism by center) and did not deviate from the Hardy-Weinberg equilibrium. Carriers of the C allele for the COX-2 -765G.C polymorphism were combined because of the low prevalence of CC participants and their similar genotypic effects. At baseline, carriers of the -765C allele did not differ in BMI or serum glucose or lipid concentrations from GG homozygotes ( Table 2) . However, the COX-2 -765G.C polymorphism was associated with lower IL-6 (P ¼ 0.002) and ICAM-1 (P ¼ 0.018) concentrations. After adjustment for confounders, these associations remained significant (Table 2 ). Serum VCAM-1 and CRP were not associated with these polymorphisms. Moreover, we found a consistent homogeneity by gender. In both men and women, the COX-2 -765G.C polymorphism was associated with lower ICAM- 1 and IL-6 concentrations (P for COX-2 3 gender: 0.900; P ¼ 0.021 for mean differences in men and P ¼ 0.037 for mean differences in women). Neither was any heterogeneity by gender for this polymorphism observed in the other variables analyzed (P for heterogeneity . 0.4). Only mean ICAM-1 concentrations differed among the IL-6 -174G.C genotypes in the sample as a whole ( Table 3) . In analyzing gene 3 gender interactions, we observed a significant interaction (P ¼ 0.002 in the unadjusted analysis; P ¼ 0.009 in the multivariate-adjusted model) in determining serum IL-6 concentrations (Fig. 1) . Thus, the IL-6 -174G.C polymorphism was associated with higher serum IL-6 concentrations in men (P ¼ 0.013), following an increasing trend. However, there was no such association in women (P ¼ 0.873).
Given that both polymorphisms determine ICAM1 concentrations for men and women, we studied the joint contribution of both genetic variants on this marker. No gene 3 gene interaction between both polymorphisms was found (P ¼ 0.722). Thus, the highest concentrations of ICAM1 (adjusted means 6 SE) were in CC homozygotes for the IL-6 -174G.C polymorphism, who were also GG homozygotes for the COX2 -765G.C polymorphism (301.3 6 23.4 mg/L). The lowest concentrations of ICAM-1 were detected in carriers of the G allele for the IL-6 -174G.C polymorphism carrying the C allele for the COX2 -765G.C polymorphism (244.3 6 18.8 mg/L) (P ¼ 0.027).
Dietary intervention and gene 3 diet interaction. At baseline, demographic, clinical, genetic, and dietary variables did not differ among the 3 groups. After the 3-mo dietary intervention with MD1VOO or MD1NUTS, the MD diet score increased in these groups ( Table 4) . More details about other dietary changes have been reported in our previous work (6) . According to the questionnaire responses, all participants, both those who received the VOO supplement as well as all those who received nuts, stated that they had consumed them. In addition, biochemical measurements in plasma and urine from the random group of participants revealed good adherence to supplemented foods. Compared with the control (CRTL) group, the MD1VOO group had increased urinary tyrosol (12 mg/L; 95% CI: 7-16; P ¼ 0.001) and hydroxytyrosol (0.08 mg/L; 95% CI: 0.05-0.011; P ¼ 0.01); those allocated to the MD1NUTS had increased plasma a-linolenic acid (60 mg/L; 95% CI: 45-79; P ¼ 0.04). Intervention with MD1VOO or MD1NUTS decreased serum inflammation markers (IL-6, ICAM-1, or VCAM-1). These markers did not decrease in the CRTL group (Table 4) .
In the present work, we specifically examined the influence of the COX-2 -765G.C and the IL-6 -174G.C polymorphism in determining these changes. We did not find gene 3 diet interactions in any group. For the COX-2 -765G.C on serum IL-6 concentrations ( Fig. 2A) , the effect of the MD in decreasing serum IL-6 concentrations was the same for both GG homozygotes and C-allele carriers (P for the global gene 3 diet interaction ¼ 0.634). We found similar results when the potential gene 3 diet interaction between the COX-2 -765G.C polymorphism and the dietary intervention on serum ICAM-1 concentrations (Fig. 2B) . We did not find significant interactions in any diet FIGURE 1 Serum IL-6 concentrations in men and women by the IL-6 -174G.C polymorphism at baseline. Values are means 6 SE, n ¼ 314 men and n ¼ 407 women and were adjusted for age, BMI, diabetes, hypertension, hyperlipidemia, tobacco smoking, MD score, and medication use (antihypertensive drugs, statins, antidiabetic drugs, nonsteroidal antiinflammatory agents, and aspirin). The P-value for the interaction term was obtained in the multivariate-interaction model. Within a gender, means without a common letter differ, P , 0.05 (Tukey test).
group but found that intervention with the MD1VOO or MD1NUTS decreased ICAM-1 concentrations independently from the COX-2 polymorphism. We did not detect gene 3 diet interactions between this polymorphism and dietary intervention in determining serum CRP or VCAM-1 concentrations (P for gene 3 diet interactions ¼ 0.259 and 0.548, respectively). Regarding the IL-6 -174G.C polymorphism, there was no modification of the effect of the corresponding dietary intervention on serum ICAM-1 concentrations (P for gene 3 diet interaction ¼ 0.392). We did not observe a diet 3 gene interaction when the combined genotype (COX-2 and IL-6) was analyzed on serum ICAM-1 concentrations (P ¼ 0.249).
Discussion
We have investigated the influence of the -765G.C COX-2 and the -174G.C IL-6 polymorphisms on serum inflammation markers in a high cardiovascular risk Mediterranean population. The associations were higher and more homogeneous by gender for the COX-2 -765G.C. Carriers of the -765C allele had significantly lower serum IL-6 and ICAM-1 concentrations. Several studies have reported a protective role of this variant, associated with a lower promoter activity (11) (12) (13) (14) 25) . Papafili et al. (11) found lower serum CRP concentrations in -765C carriers after coronary surgery. In contrast to our results, they did not find a significant association with IL-6. However, Orbe et al. (13) , in asymptomatic participants from Spain, did observe lower concentrations of both IL-6 and CRP in -765C allele carriers. Moreover, they detected lower COX-2 expression and reduced subclinical atherosclerosis. These results agreed with those obtained by Cipollone et al. (12) showing that the -765C allele was associated with a decreased risk of myocardial infarction and stroke. Nevertheless, Papafili (11), Cipolloni (12) , and Orbe (13) did not study the association of the COX-2 polymorphism with ICAM-1 or VCAM-1. In our study, we found an association of the -765G.C polymorphism with lower serum ICAM-1 but not with serum VCAM-1 concentrations. To our knowledge, this is the first study to report these results. Although both cellular adhesion molecules are considered markers of endothelial activation and atherosclerosis, there are various studies (26) (27) (28) (29) (30) that have found differences between these 2 markers regarding their specificity. When we analyzed the effect of the IL-6 -174G.C polymorphism, we found less consistent associations with serum IL-6 concentrations than when examining the COX-2 polymorphism. Although dozens of studies exist, consistency of the associations found is low (18, 19, (31) (32) (33) (34) (35) . Fishman et al. (31) demonstrated the in vitro functionality of the IL-6 -174G.C polymorphism, showing a lower expression of the -174C allele. However, the controversial results in epidemiological studies, as well as the identification of novel regulatory regions in the IL-6 promoter (32), suggest that regulation of IL-6 expression is more complex than previously thought. Hence, there are studies that associate the -174C allele with greater serum IL-6 concentrations (19, 33) and studies in which no such association was found (21, 34, 35) . These discrepancies are also found when that polymorphism is related to cardiovascular risk (17, (33) (34) (35) (36) (37) . This fact could be due to the existence of a relevant modulation depending on the characteristics of the population. Here, we found an interaction with gender; in women, serum IL-6 concentrations did not differ, whereas in men, IL-6 concentrations were significantly increased in -174C carriers. Although some studies have also reported increased serum CRP concentrations in -174C carriers (17, 21, 38) , we did not find those associations in this high cardiovascular risk Mediterranean population. However, this polymorphism was associated with higher serum ICAM-1 concentrations.
We studied whether these polymorphisms act by modulating the effect of a dietary intervention with MD, administered over 3 mo, on the decrease of serum IL-6, CRP, ICAM-1, and VCAM-1 concentrations, because we found in a previous work a beneficial effect of the MD on those markers (6) and others have reported similar decreases (4,7). We did not find significant gene 3 diet interactions for either of the inflammation markers analyzed. In the case of the COX-2 polymorphism, although at baseline, the IL-6 concentrations were higher in the -765GG homozygotes, the intervention with MD diet, either supplemented with VOO or nuts, reduced serum IL-6 concentrations in both groups. The same situation of no statistical gene 3 diet interaction was found for the reduction of serum ICAM-1. This fact, in which a dietary intervention reduces high concentrations of a risk marker in individuals with high baseline concentrations related to their genotype, has been called a ''biological'' gene 3 diet interaction (39) . The term biological interaction is commonly applied in monogenic diseases and is currently used in some dietary interventions in clinical practice to prevent the disease. A statistical interaction exists if the degree or direction of the effect of 1 factor (e.g. a polymorphism) differs according to values of a 2nd factor (e.g. a dietary intervention). Accordingly, the vast majority of reports examining gene 3 diet interactions focused on statistically significant interactions (39) . However, biological interaction needs to be considered when designing preventive and therapeutic dietary interventions to modify specific phenotypes in genetically susceptible individuals.
One of the potential limitations of our study is that an important part of the differences observed in inflammation markers might be attributed to supplementary foods, because adherence to them was higher than to the general dietary patterns.
In conclusion, the COX-2 -765C . G polymorphism is a relevant genetic marker in determining serum IL-6 and ICAM-1 concentrations in a high cardiovascular risk Mediterranean population. We did not find statistical gene 3 diet interactions, so intervention with MD1VOO or MD1NUTS reduced serum concentrations of inflammation markers regardless of the studied genotypes. Hence, this intervention, besides being beneficial for the general population, would especially benefit those participants whose genotype in the COX-2 or in the IL-6 genes provides them with higher concentrations of inflammation markers. This observation is considered a biological gene 3 diet interaction.
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